Quick Links

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Kite Pharma, Inc. and Takeda Oncology.

Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid Malignancies

Release Date: December 30, 2017
Expiration Date: December 30, 2018
Media: Internet - based


Activity Overview

Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid Malignancies consists of a series of interactive clinical vignettes, short video interviews with leading experts in hematologic malignancies, and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes and questions commonly faced in the community oncology practice setting.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Kite Pharma, Inc. and Takeda Oncology.

CME/CE Activity Table of Contents

  • Module 1: Lymphoma
  • Module 2: Multiple Myeloma
  • Module 3: Chronic Lymphocytic Leukemia

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physician assistants, etc) involved in the treatment and management of patients with hematologic malignancies.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Assess methods to stratify risk using genomic and molecular biomarkers and how they can be used to guide clinical decision making in the management of hematologic malignancies
  • Explain key evidence and how it can be applied to real-world clinical scenarios to individualize care
  • Identify interprofessional approaches to address treatment-related toxicities in patients who receive care for hematologic malignancies
  • Detail how to ensure compliance among patients who receive oral therapies for the management of their hematological malignancies
  • Describe emerging mechanistic approaches and evidence concerning novel strategies undergoing clinical development
  • Place recent clinical trial findings on emerging treatment strategies in the context of evolving treatment paradigms in the field 

Faculty, Staff, and Planners' Disclosures


John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Chair of Medical Oncology
Barts Cancer Institute
Barts and The London School of Medicine
Queen Mary University of London
London, England, United Kingdom

Disclosure: Grant/Research Support: Janssen, Acerta; Consultant/Advisory Boards: Unum, Cellectis, Celgene; Other: Honoraria from Celgene, Abbive, Acerta, Gilead, Janssen, Karyopharm, Pharmacyclis, TG Therapeutics, Roche

Ronald Levy, MD
Division of Oncology
Stanford School of Medicine
Stanford, California, USA

Disclosure: Grant/Research Support: Dynavax; Consultant/Advisory Boards: Kite, Immune Design, Five Prime, Corvus, Beigene, Innate Pharma

María-Victoria Mateos, MD, PhD
Associate Professor, Hematology
University Hospital of Salamanca
Salamanca, Spain

Disclosure: Grant/Research Support: Celgene; Consultant/Advisory Boards: Celgene, Janssen, Amgen, Takeda, Bristol-Myers Squibb

Anas Younes, MD
Professor and Chief, Lymphoma Service
Division of Hematologic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY, USA

Disclosure: Grant/Research Support: Novartis, Johnson and Johnson, Curis, Roche, Bristol-Myers Squibb; Consultant/Advisory Boards: Bayer, Bristol-Myers Squibb, Celgene, Incyte, Janssen, Sanofi, Seattle Genetics, Takeda Millennium, Genentech, Merck

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By